Johnson & Johnson JNJ MedTech Surgery Franchise — Restructuring (Note 12)
Other segment segments
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Johnson & Johnson in its filing.
Tagged under the XBRL concept us-gaap:RestructuringCharges.
The official record: Johnson & Johnson’s 10-Q, filed April 22, 2026, on SEC EDGAR. View the filing →
Ask your AI about Johnson & Johnson's medtech surgery franchise — restructuring (note 12).
Connect your AI assistant and compare segments, right in your chat.
Connect your AI

Claude
Questions, answered.
- What is Johnson & Johnson's medtech surgery franchise — restructuring (note 12)?
- Johnson & Johnson (JNJ) reported medtech surgery franchise — restructuring (note 12) of $55M in Q1 2026.
- What does medtech surgery franchise — restructuring (note 12) mean?
- This metric represents the specific costs and financial impacts associated with organizational restructuring initiatives within the MedTech Surgery business unit. It captures expenses related to workforce reductions, facility consolidations, and strategic realignment projects intended to optimize operational efficiency. These charges are typically disclosed in financial footnotes to provide transparency into non-recurring items affecting segment-level profitability.